Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 432-436, 2007.
Article
in Korean
| WPRIM
| ID: wpr-121712
ABSTRACT
Malignant pleural mesothelioma (MPM) is a rare tumor that is difficult to clearly distinguish from an adenocarcinoma but usually has a poor prognosis. Numerous cytotoxic agents have been used in the primary treatment of MPM with limited success. A complete response is unusual and a partial response occurs in less than one-third of patients. Recently, a phase III trial showed that a combination of pemetrexed with cisplatin resulted in a significantly higher response rate and median survival time than with cisplatin alone. We encountered a case of a dramatic tumor response to pemetrexed/cisplatin combination chemotherapy in patients with MPM, which was resistant to the 1st-line gemcitabine/cisplatin therapy. After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had decreased dramatically with complete symptom relief. There was no chemotherapy-related toxicity or scheduled violation. The patient is under maintenance chemotherapy with the same regimen.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Adenocarcinoma
/
Cisplatin
/
Cytotoxins
/
Tumor Burden
/
Drug Therapy, Combination
/
Maintenance Chemotherapy
/
Pemetrexed
/
Mesothelioma
Type of study:
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS